Marshall Wace, LLP Cel Sci Corp Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.58 - $4.99 $77,624 - $150,134	30,087 Added 57.13%	82,752 $372,000
Q1 2022 May 16, 2022	SELL	$3.93 - $7.7 $400,879 - $785,438	-102,005 Reduced 65.95%	52,665 $208,000
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $949,887 - $1.72 Million	133,787 Added 640.65%	154,670 $1.1 Million
Q3 2021 Nov 15, 2021	BUY	$7.64 - $12.49 $159,546 - $260,828	20,883 New	20,883 $230,000
Q1 2021 May 17, 2021	SELL	$12.0 - $27.64 $281,100 - $647,467	-23,425 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$11.05 - $16.62 $258,846 - $389,323	23,425 New	23,425 $273,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.